Skip to content

Perioperative metabolome changes in patients undergoing general anaesthesia for tumor surgery

Perioperative metabolome changes in patients undergoing general anaesthesia for tumor surgery - PeriMet

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00016686
Enrollment
30
Registered
2019-02-04
Start date
2019-02-15
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General anaesthesia C25

Interventions

Group 1: Metabolites (amino acids, carnitines, sugars, phospholipids, sphingolipids, fatty acids, bile acids, zytokines) are measured at several points of time (before induction of anaesthesia
after induction but before start of surgery
after start of surgery
60min after start of surgery
after removal of the tumor tissue
after skin suture
during postoperative care in the recovery room) from blood Plasma of patients (30 patients, , Age >18years) undergoing General anesthesia for pancreatic cancer surgery. Blood is drawn from venous cat

Sponsors

Universitätsklinikum Heidelberg Klinik für Anästhesiologie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: male; Age 18-70years; indication for whipple-surgery (pancreatic cancer surgery) for pancreatic cancer treatment; planned General anesthesia with or without epidural anaesthesia

Exclusion criteria

Exclusion criteria: female; incapacitated patients; dementia; psychotic disease; mental Retardation; neoadjuvant chemotherapy <3months before surgery; renal insufficiency (GFR <60ml/min); Diabetes type I or II with Need for drug therapy; autoimmune disorder (Lupus erythematodes, Sjögren Syndrome, Spondylitis alkylosans, CREST-Syndrome, sklerodermia, Morbus crohn, colitis ulcerosa, sarkoidose, goodpasture-syndrome, celiac disease, hashimoto-thyreoiditis, Morbus Basedow, autoimmune pancreatitis, multiple sklerosis, rheumatoid Arthritis); congenital immune disorders, iatrogene immune Suppression (Steroid therapy, Transplantation); blood transfusions <14days before surgery; therapy with immune modulating drugs (statines, Arginin, Coenzyme Q; Carnitin, Cyclosporin)

Design outcomes

Primary

MeasureTime frame
Measurement of perioperative, longitudinal metabolic changes on oncologic patients by quantitative analysis of metabolites (amino acids, carnitines, sugars, phospholipids, sphingolipids, fatty acids, bile acids, zytokines) via mass spectrometry using internal Standards in patients receiving General anesthesia during pancreatic cancer surgery (whipple's surgery)

Secondary

MeasureTime frame
Identification of possible anaesthesiologic factors that may influence metabolic changes. Generating further hypothesis for more detailed studies on the influence of anaesthesiologic procedures on cancer outcome.

Countries

Germany

Contacts

Public ContactJohanna Ohnesorge

Universitätsklinikum Heidelberg Klinik für Anästhesiologie

johanna.ohnesorge@med.uni-heidelberg.de062215632946

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026